Delivery Order SPE2DB22D3501-SPE2DB25FXK81
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $11,960.42 firm fixed price delivery order for DARZALEX FASPRO 1,800MG-30,000 15ML, with an ultimate completion date of July 8, 2025. This competitively awarded contract, which carries no set-aside designation, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a $23,920.84 delivery order to AmerisourceBergen Drug Corp for DARZALEX FASPRO 1,800MG-30,000 15ML, a specialized pharmaceutical product, with an ultimate completion date of July 30, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract represents a single delivery order issued under AmerisourceBergen's existing...
- The Defense Logistics Agency awarded a delivery order valued at $11,960.42 to AmerisourceBergen Drug Corp for DARZALEX FASPRO 1,800MG-30,000 15ML pharmaceutical product. This firm fixed price delivery order was competitively awarded without set-aside provisions and is scheduled for completion by August 20, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, which serves as the company's primary operational hub for federal...
- The Defense Logistics Agency awarded a $89,703.15 firm fixed price delivery order to AmerisourceBergen Drug Corp for DARZALEX FASPRO 1,800MG-30,000 15ML, a specialized pharmaceutical product. The contract is unclassified as a set-aside and has an ultimate completion date of September 24, 2025. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending...
- The U.S. Defense Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on June 24, 2025, for the supply of DARZALEX FASPRO 1,800MG-30,000 15ML, a specialized pharmaceutical product. This competitive, non-set-aside delivery order carries a firm fixed price ceiling value of $95,683.36 with an ultimate completion date of July 16, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its...
- The Defense Logistics Agency awarded a $23,920.84 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of DARZALEX FASPRO 1,800MG-30,000 15ML, a pharmaceutical product to be delivered to Conshohocken, Pennsylvania by August 18, 2025. This competitive award, issued under a firm fixed-price delivery order contract with no set-aside designation, represents a single transaction on AmerisourceBergen's larger pharmaceutical supply agreement with the agency. This delivery...
- The Defense Logistics Agency (DLA) awarded a $35,881.26 delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Darzalex Faspro 1,800mg-30,000 15ml pharmaceutical product, with performance completion targeted for September 9, 2025. This non-competitive delivery order employs firm fixed price pricing and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through...
- The Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Darzalex Faspro 1,800mg-30,000 15ml pharmaceutical products, with a contract ceiling value of $478,416.80. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was competitively procured. The contract is scheduled for completion by October 6, 2025, and will be performed at AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, for the supply of DARZALEX FASPRO 1,800MG-30,000 15ML pharmaceutical product. This firm fixed-price delivery order, valued at $59,802.10, was awarded on August 1, 2025, with an ultimate completion date of August 22, 2025. The contract represents a non-set-aside award issued under competitive procurement, reflecting...
- The Defense Logistics Agency awarded a $107,643.78 firm fixed-price delivery order to AmerisourceBergen Drug Corp for DARZALEX FASPRO 1,800MG-30,000 15ML pharmaceutical product, with an ultimate completion date of August 22, 2025. This non-set-aside contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The delivery location is AmerisourceBergen's...
- SPE2DB22D3501Indefinite Delivery Contract
- SPE2DB22D3501-SPE2DB25FXK81Delivery Order
The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $123,315.90 for DARZALEX FASPRO 1,800MG-30,000 15ML pharmaceutical product on September 19, 2025, with an ultimate completion date of October 10, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award to support federal medical procurement needs. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. As a comprehensive global pharmaceutical support vehicle, this prime IDC enables AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including specialty medications, brand-name and generic drugs, and vaccines. The company's demonstrated capability in federal medical procurement, evidenced through consistent competitive awards and a substantial contract portfolio with DLA, positions it as a critical vendor for Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $123.3k | 9/19/25 |